


1. A compound having the formula I



5

in which:

- Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl, wherein one or more carbon atoms of the (C₃-C₈)-cycloalkanediyl ring or the (C₃-C₈)-cycloalkenediyl ring may be replaced by oxygen atoms;
- R1, R2 independently of one another are H, F, Cl, Br, CF₃, OCF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl, SCF₃, SF₅, OCF₂-CHF₂, (C₆-C₁₀)-aryl, (C₆-C₁₀)-aryloxy, OH, NO₂; or
- R1 and R2 together with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C₆-C₁₀)-aryl, (C₅-C₁₁)-heteroaryl;
- R3 is H, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, (C₁-C₃)-alkyl-(C₃-C₈)-cycloalkyl, phenyl, (C₁-C₃)-alkyl-phenyl, (C₅-C₆)-heteroaryl, (C₁-C₃)-alkyl-(C₅-C₆)-heteroaryl or (C₁-C₃)-alkyl which is fully or partially substituted by F;
- W is CH or N if o = 1;
- W is O, S or NR₁₀ if o = 0;
- X is (C₁-C₆)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;
- n is 0-2;
- R4 is H or (C₁-C₆)-alkyl;

- 5
10
15
20
25
30
35
- R5 is H or (C₁-C₆)-alkyl;
- R6 is H, (C₁-C₆)-alkyl or F;
- R7 is H; F; (C₁-C₆)-alkoxy; (C₂-C₆)-alkenyl; (C₂-C₆)-alkynyl; (C₃-C₈)-cycloalkyl; phenyl which may be unsubstituted or substituted by one or more radicals from the group consisting of hydroxy, (C₁-C₆)-alkoxy, F and CF₃; (C₁-C₆)-alkyl which may be unsubstituted or substituted by one or more radicals selected from the group consisting of hydroxyl, phenyl, (C₅-C₁₁)-heteroaryl, (C₁-C₆)-alkoxy and NR₁₁R₁₂;
- with the proviso that R7 is not NR₁₁R₁₂ or (C₁-C₆)-alkoxy if R6 = F;
- R7 and R9 together with the atoms that carry them are pyrrolidine or piperidine if n = 0;
- R6 and R7 together with the carbon atom that carries them are (C₃-C₈)-cycloalkyl;
- R8 is H, (C₁-C₆)-alkyl;
- R9 is H, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₄)-alkyl-(C₆-C₁₀)-aryl, (C₁-C₄)-alkyl-(C₅-C₁₁)-heteroaryl, (C₁-C₄)-alkyl-O-(C₁-C₄)-alkyl, phenyl-(C₁-C₄)-alkyl, (C₅-C₆)-heteroaryl-(C₁-C₄)-alkyl;
- R10 is H, (C₁-C₆)-alkyl-phenyl, (C₁-C₆)-alkyl;
- R11 is H, (C₁-C₆)-alkyl-phenyl, (C₁-C₆)-alkyl;
- R12 is H, (C₁-C₆)-alkyl-phenyl, (C₁-C₆)-alkyl;
- a physiologically acceptable salt of the compound;
a solvate of the compound; or
a physiologically effective derivative of the compound.

2. The compound of Claim 1, in which

- 5 Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl,
 wherein one carbon atom of the (C₃-C₈)-cycloalkanediyl ring
 or the (C₃-C₈)-cycloalkenediyl ring may be replaced by an
 oxygen atom;
- 10 X is (C₁-C₆)-alkanediyl, wherein the C1 or C2 carbon atom (to
 Ring A) of the alkanediyl group may be replaced by an
 oxygen atom.

3. The compound of Claim 1, in which

- 15 Ring A is cis-cyclohexane-1,3-diyl
- R1 is Br, CF₃, OCF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl;
- R2 is H, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl or
- 20 R1 and R2 together with the phenyl ring form naphthyl;
- R3 is CF₃, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, phenyl;
- 25 W is CH if o = 1;
- X is CH₂O or CH₂-O-CH₂;
- n is 0;
- 30 R6 is H or (C₁-C₆)-alkyl;
- R7 is (C₁-C₆)-alkyl, where alkyl may be unsubstituted or
 substituted by phenyl;
- 35 R7 and R9 together with the atoms that carry them are pyrrolidine if
 n = 0;
- R6 and R7 together with the carbon atom that carries them are (C₃-C₆)-

cycloalkyl;

R8 is H; and

5 R9 is H, (C₁-C₆)-alkyl or benzyl.

4. A pharmaceutical composition, comprising the compound of Claim 1
and a pharmaceutically acceptable carrier.
- 10 5. The pharmaceutical composition of Claim 4, further comprising an
active compound having a favorable effect on a metabolic disorder or
disease.
- 15 6. The pharmaceutical composition of Claim 4, further comprising an
antidiabetic.
7. The pharmaceutical composition of Claim 4, further comprising a
lipid modulator.
- 20 8. A method for treating and/or preventing a disorder of fatty acid
metabolism and/or a glucose utilization disorder in a patient, comprising
administering a therapeutically effective amount of the compound of Claim
1 to the patient.
- 25 9. A method for treating a disorder in which insulin resistance is
involved in a patient, comprising administering a therapeutically effective
amount of the compound of Claim 1 to the patient.
- 30 10. A method for treating and/or preventing diabetes mellitus and its
sequelae in a patient, comprising administering a therapeutically effective
amount of the compound of Claim 1 to the patient.
- 35 11. A method for treating and/or preventing dyslipidemias and their
sequelae in a patient, comprising administering a therapeutically effective
amount of the compound of Claim 1 to the patient.
12. A method for treating and/or preventing a disease state or disorder
state in a patient associated with a metabolic syndrome, comprising

administering a therapeutically effective amount of the compound of Claim 1 to the patient.

13. The method of Claim 8, further comprising administering in
5 combination at least one further active compound for treating and/or preventing a disorder of the fatty acid metabolism and/or glucose utilization disorder.
14. The method of Claim 9, further comprising administering a at least
10 one further active compound for treating and/or preventing a disorder in which insulin is involved.
15. A process for preparing a pharmaceutical comprising the
15 compound of Claim 1, comprising the steps of:
- (a) mixing the compound with a pharmaceutically acceptable carrier,
and;
 - (b) bringing the mixture into a form suitable for administration.
20
16. A pharmaceutical composition comprising the compound of Claim 2
and a pharmaceutically acceptable carrier.
17. A method for treating and/or preventing a disorder of fatty acid
25 metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.
18. A method for treating a disorder in which insulin resistance is
30 involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.
19. A method for treating and/or preventing diabetes mellitus and its
35 sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.
20. A method for treating and/or preventing dyslipidemias and their
sequelae in a patient, comprising administering a therapeutically effective
amount of the compound of Claim 2 to the patient.

21. A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.
22. A pharmaceutical composition comprising the compound of Claim 3 and a pharmaceutically acceptable carrier.
23. A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.
24. A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.
25. A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.
26. A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.
27. A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.